Takeda Pharmaceutical Company Limited Research and Development Expense
Takeda Pharmaceutical Company Limited (TAK) reported Research and Development Expense of JPY 730.23 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2025-06-25
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-03-31 | 730.23B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | 729.92B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | 633.33B JPY 20-F · filed 2025-06-25 |
| 2022-03-31 | 526.09B JPY 20-F · filed 2024-06-26 |
| 2021-03-31 | 455.83B JPY 20-F · filed 2023-06-28 |
| 2020-03-31 | 492.38B JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | 368.30B JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | 325.44B JPY 20-F · filed 2020-06-24 |
| 2017-03-31 | 312.30B JPY 20-F · filed 2019-06-27 |